Condition: Combined Pre- and Post-capillary Pulmonary Hypertension · CpcPH · HFmrEF · Sponsor: Gachon University Gil Medical Center
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks. Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.
This description comes directly from the study's public registry record.
Wook-Jin Chung, MD, PhD · 82-32-460-3663 · heart@gilhospital.com
Always discuss trial participation with your own doctor first.
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| Chungbuk National University Hospital | Chungju, South Korea | Not Yet Recruiting |
| Keimyung University Dongsan Hospital | Daegu, South Korea | Recruiting |
| Chungnam National University Hospital | Daejeon, South Korea | Recruiting |
| Chonnam National University Hospital | Gwangju, South Korea | Recruiting |
| Incheon Sejong Hospital | Incheon, South Korea | Not Yet Recruiting |
| Gachon University Gil Hospital | Incheon, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Not Yet Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Not Yet Recruiting |
| The Catholic University of Korea, Seoul St.Mary | Seoul, South Korea | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07147114